Angel Biotech acquires collagen plant in UK
ABH’s wholly owned subsidiary, Angel Biomedical Ltd (ABL) will take ownership of the manufacturing plant. The 6,500ft² facility comprises one large Grade C clean room, two smaller grade
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.